Now, AI tools to predict severity in respiratory issues in Covid-19 patients

Hemani Sheth Mumbai | Updated on March 31, 2020 Published on March 31, 2020

Researchers have developed an Artificial Intelligence (AI) tool that can predict the probability of a newly infected Covid-19 patient developing a severe respiratory disease, according to media reports.

The study has been published in the journal Computers, Materials & Continua.

Co-author Anasse Bari, a clinical assistant professor in Computer Science at the Courant Institute of Mathematical Sciences at New York University had said that the goal of the research was to design and deploy a tool that uses AI capabilities for predictive analysis to flag patients that can develop coronavirus-related severities, the report said.

Once deployed, doctors can prioritize patient care based on their potential to develop severe respiratory issues using the AI algorithm, Al Jazeera reported.

The tool discovered multiple indicators that can be used to predict if a patient would develop "acute respiratory disease syndrome" (ARDS), a severe complication of Covid-19. ARDS fills the lungs with fluid and is the cause of mortality for about 50 per cent of coronavirus patients who develop this, the report said. Neither age nor sex was among these indicators.

The AI algorithm was based on machine learning using data from 53 coronavirus patients across two hospitals in Wenzhou, China, it said.

The tool was able to predict the risk of developing ARDS in patients with up to 80 per cent accuracy.

AI tools to combat Covid-19

AI has been used by researchers and scientists on multiple occasions to develop tools that help in combating the coronavirus pandemic in multiple ways.

Apollo Hospitals, for example, recently rolled out an AI-based self-assessment test that can help users predict their risk level in contracting Covid-19. The tool predicts the risk level using survey questions based on travel history, health and symptoms.

Another start-up, Innoplexus AG, founded by Indians and headquartered in Germany has claimed to have developed an AI-enabled drug discovery platform. The platform helps medical professionals arrive at combinations of existing drugs that may prove more efficacious in treating Covid-19 cases, according to previous reports.

Published on March 31, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.